New concept of vascular calcification and metabolism

Current Vascular Pharmacology

Volumn 9, Issue 1, 2011, Pages 124-127

  Nakagami, Hironori ^a   Osako, Mariana K ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Ezetimibe; RANKL; Vascular calcification

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ADSORPTION; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AORTA INTIMA; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL COMPLIANCE; BONE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INTIMAL CALCIFICATION; LIPID DIET; LIPID METABOLISM; LOW DRUG DOSE; NONHUMAN; OVARIECTOMY; OXIDATIVE STRESS; POSTMENOPAUSE OSTEOPOROSIS; PRECIPITATION; PROTEIN EXPRESSION;

ANIMALS; ATHEROSCLEROSIS; AZETIDINES; CALCINOSIS; HUMANS; LIPID METABOLISM;

EID: 78650953134     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111793744742     Document Type: Article

References (38)

1. Eggen DA, Strong JP, McGill HC Jr. Coronary calcification. Relationship to clinically significant coronary lesions and race, sex, and topographic distribution. Circulation 1965; 32: 948-55.
2. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation 1992; 86: 64-70.
3. Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation 1996; 93: 1951-3.
4. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996; 94: 1175-92.
5. Yu S. Calcification process in atherosclerosis. In: Wagner WB, Clarkson TB, Eds. Arterial Mesenchyme and Atherosclerosis. New York: Plenum Press, 1974; pp. 403-25.
6. Moon J. Factors affecting arterial calcification associated with atherosclerosis. Atherosclerosis 1972; 16: 119-26.
7. Blumenthal HL, Wheeler, PA. Calcification of the media of the human aorta and its relation to intimal arteriosclerosis, aging and disease. Am J Pathol 1944; 20: 665-87.
8. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-57.
9. Parhami F, Bostrom K, Watson K, Demer LL. Role of molecular regulation in vascular calcification. J Atheroscler Thromb 1996; 3: 90-4.
10. Frye MA, Melton LJ 3rd, Bryant SC, et al. Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-94.
11. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Cal-cif Tissue Int 2001; 68: 271-6.
12. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003.
13. Doherty TM, Uzui H, Fitzpatrick LA, et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J 2002; 16: 577-82.
14. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteopo-rosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-74.
15. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9.
16. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-5.
17. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
18. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
19. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
20. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
21. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclasto-genesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-37.
22. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Bio-chem Biophys Res Commun 1998; 247: 610-5.
23. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
24. Banks LM, Lees B, MacSweeney JE, Stevenson JC. Effect of de-generative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?. Eur J Clin Invest 1994; 24: 813-7.
25. Detrano RC, Doherty TM, Davies MJ, Stary HC. Predicting coro-nary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol 2000; 25: 374-402.
26. Virmani R, Burke AP, Farb A. Plaque morphology in sudden coronary death. Cardiologia 1998; 43: 267-71.
27. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70.
28. Pedersen TR, Kjekshus J, Berg K, et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
29. Grundy SM. Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 1983; 3: 71-96.
30. Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
31. Rosenblum SB, Huynh T, Afonso A, et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 1998; 41: 973-80.
32. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001; 415: 79-84.
33. Altmann SW, Davis HR Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
34. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-7.
35. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hy-perlipidemia. J Atheroscler Thromb 2007; 14: 99-108.
36. Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009; 203: 51-8.
37. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-70.
38. Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and val-sartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 4369-76.